Millennium Management’s Relmada Therapeutics RLMD Stock Holding History

Millennium Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-85,000	Closed	-$3.15M	–	6966
2022 Q3	$3.15M	Buy	+85,000	New	+$2.35M	﹤0.01%	3346
2022 Q2	–	Sell	-30,000	Closed	-$810K	–	7419
2022 Q1	$810K	Buy	+30,000	New	+$620K	﹤0.01%	4735
2021 Q2	–	Sell	-70,000	Closed	-$2.46M	–	7017
2021 Q1	$2.46M	Sell	70,000 -15,000	-18%	-$525K	﹤0.01%	3336
2020 Q4	$2.73M	Buy	85,000 +27,500	+48%	+$945K	﹤0.01%	2981
2020 Q3	$2.16K	Buy	57,500 +7,500	+15%	+$290K	﹤0.01%	2538
2020 Q2	$2.24M	Buy	+50,000	New	+$2.11M	﹤0.01%	2440

Other funds holding RLMD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

SSC

Spruce Street Capital New York $416M AUM

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management's RLMD Position: Q1 2026 in Review

Millennium Management increased its Relmada Therapeutics (RLMD) stake by 134% in Q1 2026, buying an estimated $10.6M and bringing the position to 3,907,265 shares worth $27.2M. The position accounts for 0.01% of the portfolio, ranked #1295.

Millennium Management first reported a position in RLMD in Q4 2019 and has held it in 21 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

Millennium Management held 3,907,265 shares of Relmada Therapeutics worth $27.2M as of Q1 2026.
Millennium Management bought 2,234,248 Relmada Therapeutics shares in Q1 2026, an estimated $10.6M.
Relmada Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1295 holding.
Millennium Management first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 21 quarters since.
103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.